Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists,… Read More

Emerging in the landscape of excess body fat therapy, retatrutide is a different strategy. Beyond many current medications, retatrutide operates as a double agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) binding sites. T… Read More